NASDAQ:EXEL

Exelixis (EXEL) Stock Price, News & Analysis

Exelixis logo
$35.00 +0.51 (+1.48%)
Closing price 02/14/2025 04:00 PM Eastern
Extended Trading
$34.13 -0.87 (-2.49%)
As of 02/14/2025 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Exelixis Stock (NASDAQ:EXEL)

Key Stats

Today's Range
$34.18
$35.29
50-Day Range
$32.38
$37.27
52-Week Range
$20.14
$37.59
Volume
2.85 million shs
Average Volume
2.60 million shs
Market Capitalization
$10.00 billion
P/E Ratio
22.44
Dividend Yield
N/A
Price Target
$37.24
Consensus Rating
Moderate Buy

Company Overview

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Exelixis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
93rd Percentile Overall Score

EXEL MarketRank™: 

Exelixis scored higher than 93% of companies evaluated by MarketBeat, and ranked 46th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Exelixis has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 12 buy ratings, 7 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Exelixis has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Exelixis' stock forecast and price target.
  • Earnings Growth

    Earnings for Exelixis are expected to grow by 11.49% in the coming year, from $1.74 to $1.94 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Exelixis is 22.44, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.29.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Exelixis is 22.44, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 17.00.

  • Price to Earnings Growth Ratio

    Exelixis has a PEG Ratio of 0.63. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Exelixis has a P/B Ratio of 4.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Exelixis' valuation and earnings.
  • Percentage of Shares Shorted

    4.72% of the float of Exelixis has been sold short.
  • Short Interest Ratio / Days to Cover

    Exelixis has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Exelixis has recently decreased by 9.47%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Exelixis does not currently pay a dividend.

  • Dividend Growth

    Exelixis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.72% of the float of Exelixis has been sold short.
  • Short Interest Ratio / Days to Cover

    Exelixis has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Exelixis has recently decreased by 9.47%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Exelixis has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 62 news articles for Exelixis this week, compared to 11 articles on an average week.
  • Search Interest

    22 people have searched for EXEL on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.
  • MarketBeat Follows

    14 people have added Exelixis to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Exelixis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,981,864.00 in company stock.

  • Percentage Held by Insiders

    Only 2.85% of the stock of Exelixis is held by insiders.

  • Percentage Held by Institutions

    85.27% of the stock of Exelixis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Exelixis' insider trading history.
Receive EXEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exelixis and its competitors with MarketBeat's FREE daily newsletter.

EXEL Stock News Headlines

William Blair Predicts Exelixis' Q1 Earnings (NASDAQ:EXEL)
DividendStocks for Beginners
If you’re not familiar with how to build a strong, reliable dividend portfolio… or where to begin… We’ve got the hookup for you. A young investor who’s obsessed with dividends put together a set of 5 dividend “cheat sheets” meant to take you from 0 to what could be a full blown dividend portfolio as quickly as possible… The best part? Right now, the five dividend cheat sheets are FREE
Exelixis (NASDAQ:EXEL) Shares Up 6.7% After Analyst Upgrade
Exelixis price target raised to $36 from $30 at Stifel
Exelixis price target raised to $45 from $38 at Citi
See More Headlines

EXEL Stock Analysis - Frequently Asked Questions

Exelixis' stock was trading at $33.30 at the start of the year. Since then, EXEL shares have increased by 5.1% and is now trading at $35.00.
View the best growth stocks for 2025 here
.

Exelixis, Inc. (NASDAQ:EXEL) posted its earnings results on Tuesday, February, 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.51 by $0.03. Exelixis had a trailing twelve-month return on equity of 20.99% and a net margin of 22.43%.

Exelixis' top institutional investors include Vanguard Group Inc. (10.31%), Renaissance Technologies LLC (5.36%), LSV Asset Management (2.86%) and Fuller & Thaler Asset Management Inc. (2.67%). Insiders that own company stock include David Edward Johnson, Christopher J Senner, Dana Aftab, Jeffrey Hessekiel, Lance Willsey, Peter Lamb, Jack L Wyszomierski, Patrick J Haley, George Poste, Maria C Freire, Maria C Freire, Alan M Garber, Carl B Feldbaum and Stelios Papadopoulos.
View institutional ownership trends
.

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Exelixis investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Humana (HUM), Arista Networks (ANET) and Adobe (ADBE).

Company Calendar

Last Earnings
2/11/2025
Today
2/15/2025
Next Earnings (Confirmed)
4/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:EXEL
CUSIP
30161Q10
Employees
1,310
Year Founded
1994

Price Target and Rating

Average Stock Price Target
$37.24
High Stock Price Target
$45.00
Low Stock Price Target
$29.00
Potential Upside/Downside
+6.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.55
Research Coverage
20 Analysts

Profitability

Net Income
$207.76 million
Pretax Margin
28.82%

Debt

Sales & Book Value

Annual Sales
$1.83 billion
Cash Flow
$0.80 per share
Book Value
$7.47 per share

Miscellaneous

Free Float
277,440,000
Market Cap
$10.00 billion
Optionable
Optionable
Beta
0.53

Social Links

10 Best Stocks to Own in 2025 Cover

Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:EXEL) was last updated on 2/15/2025 by MarketBeat.com Staff
From Our Partners